Pesquisas sobre eficácia do tratamento: Agomelatina

Eficácia: Controle – 49,06%

Rigor da pesquisa: 1 2 3 4 5 6 7

Quantidade de participantes: 212

Data: 10/2006

País(es): Reino Unido Reino Unido

Stuart A. Montgomery

Major depressive disorders: clinical efficacy and tolerability of agomelatine, a new melatonergic agonist

https://www.sciencedirect.com/science/article/abs/pii/S0924977X06700098

Eficácia: Controle – 59,46%

Remissão – 16,89%

Rigor da pesquisa: 1 2 3 4 5 6 7

Quantidade de participantes: 222

Data: 03/2013

País(es): Argentina, Finlândia, México … (+2) Argentina, Finlândia, México, Portugal, Romênia

Objetivo: O presente estudo controlado por placebo avaliou a eficácia, tolerabilidade e segurança do tratamento de 8 semanas com agomelatina (25–50 mg/dia por via oral) em pacientes idosos com transtorno depressivo maior (TDM). Método: Pacientes idosos a

The Efficacy of Agomelatine in Elderly Patients with Recurrent Major Depressive Disorder: A Placebo-Controlled Study

https://www.psychiatrist.com/wp-content/uploads/2021/02/13115_efficacy-agomelatine-elderly-patients-recurrent-major.pdf

Eficácia: Controle – 76,67%

Remissão – 33,33%

Rigor da pesquisa: 1 2 3 4 5 6 7

Quantidade de participantes: 60

Data: 11/2016

País(es): Turquia Turquia

Esma Akpınar, Cem Cerit , Anıl Talas , Ümit Tural

Agomelatine versus Sertraline: An Observational, Open-labeled and 12 Weeks Follow-up Study on Efficacy and Tolerability

https://pmc.ncbi.nlm.nih.gov/articles/PMC5083946/

Eficácia: Controle – 78,26%

Remissão – 55,80%

Rigor da pesquisa: 1 2 3 4 5 6 7

Quantidade de participantes: 411

Data: 09/2015

País(es): Argentina, Bielorrússia, Bulgária … (+3) Argentina, Bielorrússia, Bulgária, Finlândia, Eslováquia, Ucrânia

Sidney H. Kennedy , Alla Avedisova , Carole Belaïdi , Françoise Picarel-Blanchot , Christian de Bodinat

Sustained efficacy of agomelatine 10 mg, 25 mg, and 25–50 mg on depressive symptoms and functional outcomes in patients with major depressive disorder. A placebo-controlled study over 6 months.

https://www.google.com/url?q=https://www.sciencedirect.com/science/article/abs/pii/S0924977X1500293X&sa=D&source=editors&ust=1781016132240943&usg=AOvVaw3LF--7aLNc5xTmzVZ2Lpss

Eficácia: Controle – 71,30%

Rigor da pesquisa: 1 2 3 4 5 6 7

Quantidade de participantes: 2034

Data: 01/2013

País(es): —

Siegfried Kasper , Emmanuelle Corruble , Anthony Hale , Patrick Lemoine , Stuart A. Montgomery and Maria-Antonia Quera-Salva

Antidepressant efficacy of agomelatine versus SSRI/SNRI: results from a pooled analysis of head-to-head studies without a placebo control

https://journals.lww.com/intclinpsychopharm/abstract/2013/01000/antidepressant_efficacy_of_agomelatine_versus.2.aspx

Eficácia: Controle – 66,15%

Remissão – 31,54%

Rigor da pesquisa: 1 2 3 4 5 6 7

Quantidade de participantes: 264

Data: 06/2018

País(es): China China

Yu, Yi-Min MD; Gao, Ke-Run MD, PhD; Yu, Hao PhD; Shen, Yi-Feng MD, PhD; Li, Hua-Fang MD, PhD

Efficacy and Safety of Agomelatine vs Paroxetine Hydrochloride in Chinese Han Patients with Major Depressive Disorder A Multicentre, Double-Blind, Noninferiority, Randomized Controlled Trial

https://journals.lww.com/psychopharmacology/abstract/2018/06000/efficacy_and_safety_of_agomelatine_vs_paroxetine.11.aspx